New US Guidelines and FDA Approval Transform Cholesterol Treatment

WHO:

CNN - Dr. Leana Wen, emergency physician and clinical associate professor at George Washington University.

The Times of India - Dr. Ambuj Roy, Professor of Cardiology at AIIMS Delhi.

WHAT:

CNN - An estimated 21.5 million additional adults in the United States may now be eligible for statins under updated cholesterol treatment guidelines.

CNN - The total number of Americans eligible for statins could reach about 87.5 million people, or more than half of adults ages 30 to 79.

The Times of India - The US FDA approved Lipfendra, the world's first oral PCSK9 inhibitor, for adults with high cholesterol.

The Times of India - Clinical trials involving 3,207 adults found that Lipfendra reduced LDL cholesterol by 56-59% over 24 weeks in patients already on maximally tolerated statins.

WHERE:

The Times of India - The approval of Lipfendra is significant for patients in the United States, but it is not expected to be available in India immediately.

WHEN:

CNN - The updated cholesterol treatment guidelines were issued in 2026.

The Times of India - The clinical trials for Lipfendra were conducted over a duration of 24 weeks.

WHY:

CNN - The updated guidelines aim to identify adults earlier who may benefit from preventive measures, such as statin therapy, to reduce the risk of cardiovascular disease.

The Times of India - Many high-risk patients continue to have elevated LDL cholesterol despite treatment with standard oral medicines.

HOW:

CNN - The new guidelines expanded eligibility for statin therapy by increasing the age range for cardiovascular risk assessment to adults ages 30 to 79 and lowering the thresholds for categorizing cardiovascular risk.

The Times of India - Lipfendra offers an oral alternative to cholesterol-lowering injections, providing a new option for patients whose cholesterol remains uncontrolled despite existing therapy.

(UPDATED July 27, 2026 17:36 UTC)

An estimated 21.5 million additional adults in the United States may now be eligible for statins under updated cholesterol treatment guidelines issued in 2026, potentially bringing the total number of eligible Americans to about 87.5 million, which is more than half of adults ages 30 to 79. In a significant development, the US FDA has approved Lipfendra, the world's first oral PCSK9 inhibitor, which has shown to reduce LDL cholesterol by 56 to 59 percent over 24 weeks in clinical trials involving over 3,200 adults already on maximally tolerated statins. While this approval is a breakthrough for patients in the United States, it is not expected to be available in India immediately, highlighting the ongoing challenge many high-risk patients face with elevated LDL cholesterol despite standard treatments.